nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—L-Phenylalanine—Liothyronine—hypothyroidism	0.757	1	CrCrCtD
Lisdexamfetamine—SLC18A2—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.0061	0.105	CbGpPWpGaD
Lisdexamfetamine—Acute coronary syndrome—Liothyronine—hypothyroidism	0.00591	0.0338	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Liothyronine—hypothyroidism	0.00588	0.0336	CcSEcCtD
Lisdexamfetamine—SLC18A2—Neurotransmitter Release Cycle—SLC5A7—hypothyroidism	0.00466	0.0806	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.0041	0.071	CbGpPWpGaD
Lisdexamfetamine—Hypertension—Liothyronine—hypothyroidism	0.00405	0.0232	CcSEcCtD
Lisdexamfetamine—SLC6A2—Monoamine Transport—SLC5A7—hypothyroidism	0.0039	0.0674	CbGpPWpGaD
Lisdexamfetamine—Affect lability—Levothyroxine—hypothyroidism	0.00376	0.0215	CcSEcCtD
Lisdexamfetamine—Affect lability—Dextrothyroxine—hypothyroidism	0.00376	0.0215	CcSEcCtD
Lisdexamfetamine—Tachycardia—Liothyronine—hypothyroidism	0.00373	0.0214	CcSEcCtD
Lisdexamfetamine—Irritability—Levothyroxine—hypothyroidism	0.00365	0.0209	CcSEcCtD
Lisdexamfetamine—Irritability—Dextrothyroxine—hypothyroidism	0.00365	0.0209	CcSEcCtD
Lisdexamfetamine—SLC6A3—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00364	0.0629	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—SLC5A7—hypothyroidism	0.00345	0.0597	CbGpPWpGaD
Lisdexamfetamine—Body temperature increased—Liothyronine—hypothyroidism	0.00302	0.0173	CcSEcCtD
Lisdexamfetamine—Weight decreased—Dextrothyroxine—hypothyroidism	0.00299	0.0171	CcSEcCtD
Lisdexamfetamine—Weight decreased—Levothyroxine—hypothyroidism	0.00299	0.0171	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.0029	0.0166	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.0029	0.0166	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.00289	0.0165	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Levothyroxine—hypothyroidism	0.00289	0.0165	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Liotrix—hypothyroidism	0.00287	0.0164	CcSEcCtD
Lisdexamfetamine—Affect lability—Liotrix—hypothyroidism	0.00277	0.0158	CcSEcCtD
Lisdexamfetamine—SLC18A2—Synaptic Vesicle Pathway—CLTC—hypothyroidism	0.00276	0.0478	CbGpPWpGaD
Lisdexamfetamine—Irritability—Liotrix—hypothyroidism	0.00268	0.0154	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00238	0.0412	CbGpPWpGaD
Lisdexamfetamine—Nervousness—Dextrothyroxine—hypothyroidism	0.00224	0.0128	CcSEcCtD
Lisdexamfetamine—Nervousness—Levothyroxine—hypothyroidism	0.00224	0.0128	CcSEcCtD
Lisdexamfetamine—SLC6A3—nerve—hypothyroidism	0.00222	0.205	CbGeAlD
Lisdexamfetamine—Weight decreased—Liotrix—hypothyroidism	0.0022	0.0126	CcSEcCtD
Lisdexamfetamine—Tremor—Levothyroxine—hypothyroidism	0.00216	0.0123	CcSEcCtD
Lisdexamfetamine—Tremor—Dextrothyroxine—hypothyroidism	0.00216	0.0123	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Liotrix—hypothyroidism	0.00214	0.0122	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Liotrix—hypothyroidism	0.00212	0.0122	CcSEcCtD
Lisdexamfetamine—Agitation—Dextrothyroxine—hypothyroidism	0.00212	0.0121	CcSEcCtD
Lisdexamfetamine—Agitation—Levothyroxine—hypothyroidism	0.00212	0.0121	CcSEcCtD
Lisdexamfetamine—Angioedema—Dextrothyroxine—hypothyroidism	0.0021	0.012	CcSEcCtD
Lisdexamfetamine—Angioedema—Levothyroxine—hypothyroidism	0.0021	0.012	CcSEcCtD
Lisdexamfetamine—Palpitations—Levothyroxine—hypothyroidism	0.00203	0.0116	CcSEcCtD
Lisdexamfetamine—Palpitations—Dextrothyroxine—hypothyroidism	0.00203	0.0116	CcSEcCtD
Lisdexamfetamine—Convulsion—Dextrothyroxine—hypothyroidism	0.00199	0.0114	CcSEcCtD
Lisdexamfetamine—Convulsion—Levothyroxine—hypothyroidism	0.00199	0.0114	CcSEcCtD
Lisdexamfetamine—Anxiety—Dextrothyroxine—hypothyroidism	0.00195	0.0112	CcSEcCtD
Lisdexamfetamine—Anxiety—Levothyroxine—hypothyroidism	0.00195	0.0112	CcSEcCtD
Lisdexamfetamine—Tachycardia—Dextrothyroxine—hypothyroidism	0.00183	0.0105	CcSEcCtD
Lisdexamfetamine—Tachycardia—Levothyroxine—hypothyroidism	0.00183	0.0105	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00182	0.0104	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00182	0.0104	CcSEcCtD
Lisdexamfetamine—SLC6A2—nerve—hypothyroidism	0.00179	0.166	CbGeAlD
Lisdexamfetamine—Insomnia—Dextrothyroxine—hypothyroidism	0.0017	0.00972	CcSEcCtD
Lisdexamfetamine—Insomnia—Levothyroxine—hypothyroidism	0.0017	0.00972	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00167	0.00958	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Levothyroxine—hypothyroidism	0.00167	0.00958	CcSEcCtD
Lisdexamfetamine—Nervousness—Liotrix—hypothyroidism	0.00164	0.00941	CcSEcCtD
Lisdexamfetamine—Fatigue—Levothyroxine—hypothyroidism	0.00162	0.00927	CcSEcCtD
Lisdexamfetamine—Fatigue—Dextrothyroxine—hypothyroidism	0.00162	0.00927	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.0016	0.0278	CbGpPWpGaD
Lisdexamfetamine—Vision blurred—Liotrix—hypothyroidism	0.0016	0.00913	CcSEcCtD
Lisdexamfetamine—Tremor—Liotrix—hypothyroidism	0.00159	0.00908	CcSEcCtD
Lisdexamfetamine—Agitation—Liotrix—hypothyroidism	0.00156	0.0089	CcSEcCtD
Lisdexamfetamine—Angioedema—Liotrix—hypothyroidism	0.00155	0.00885	CcSEcCtD
Lisdexamfetamine—Palpitations—Liotrix—hypothyroidism	0.0015	0.00856	CcSEcCtD
Lisdexamfetamine—Urticaria—Dextrothyroxine—hypothyroidism	0.00149	0.00854	CcSEcCtD
Lisdexamfetamine—Urticaria—Levothyroxine—hypothyroidism	0.00149	0.00854	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00148	0.0085	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Levothyroxine—hypothyroidism	0.00148	0.0085	CcSEcCtD
Lisdexamfetamine—Convulsion—Liotrix—hypothyroidism	0.00147	0.00839	CcSEcCtD
Lisdexamfetamine—Hypertension—Liotrix—hypothyroidism	0.00146	0.00836	CcSEcCtD
Lisdexamfetamine—Anxiety—Liotrix—hypothyroidism	0.00144	0.00822	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00142	0.0246	CbGpPWpGaD
Lisdexamfetamine—Anaphylactic shock—Liotrix—hypothyroidism	0.00138	0.00791	CcSEcCtD
Lisdexamfetamine—Tachycardia—Liotrix—hypothyroidism	0.00135	0.00772	CcSEcCtD
Lisdexamfetamine—Asthenia—Dextrothyroxine—hypothyroidism	0.00135	0.00771	CcSEcCtD
Lisdexamfetamine—Asthenia—Levothyroxine—hypothyroidism	0.00135	0.00771	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.00134	0.0231	CbGpPWpGaD
Lisdexamfetamine—Hyperhidrosis—Liotrix—hypothyroidism	0.00134	0.00764	CcSEcCtD
Lisdexamfetamine—Anorexia—Liotrix—hypothyroidism	0.00132	0.00754	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00129	0.00735	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Levothyroxine—hypothyroidism	0.00129	0.00735	CcSEcCtD
Lisdexamfetamine—Insomnia—Liotrix—hypothyroidism	0.00125	0.00715	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Liotrix—hypothyroidism	0.00123	0.00705	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Liotrix—hypothyroidism	0.0012	0.00687	CcSEcCtD
Lisdexamfetamine—Vomiting—Levothyroxine—hypothyroidism	0.00119	0.00683	CcSEcCtD
Lisdexamfetamine—Vomiting—Dextrothyroxine—hypothyroidism	0.00119	0.00683	CcSEcCtD
Lisdexamfetamine—Fatigue—Liotrix—hypothyroidism	0.00119	0.00682	CcSEcCtD
Lisdexamfetamine—Rash—Dextrothyroxine—hypothyroidism	0.00118	0.00678	CcSEcCtD
Lisdexamfetamine—Rash—Levothyroxine—hypothyroidism	0.00118	0.00678	CcSEcCtD
Lisdexamfetamine—Dermatitis—Dextrothyroxine—hypothyroidism	0.00118	0.00677	CcSEcCtD
Lisdexamfetamine—Dermatitis—Levothyroxine—hypothyroidism	0.00118	0.00677	CcSEcCtD
Lisdexamfetamine—Constipation—Liotrix—hypothyroidism	0.00118	0.00676	CcSEcCtD
Lisdexamfetamine—Headache—Dextrothyroxine—hypothyroidism	0.00118	0.00673	CcSEcCtD
Lisdexamfetamine—Headache—Levothyroxine—hypothyroidism	0.00118	0.00673	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC5A7—hypothyroidism	0.00116	0.02	CbGpPWpGaD
Lisdexamfetamine—Nausea—Dextrothyroxine—hypothyroidism	0.00112	0.00638	CcSEcCtD
Lisdexamfetamine—Nausea—Levothyroxine—hypothyroidism	0.00112	0.00638	CcSEcCtD
Lisdexamfetamine—Urticaria—Liotrix—hypothyroidism	0.0011	0.00628	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Liotrix—hypothyroidism	0.00109	0.00625	CcSEcCtD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.00108	0.0187	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC5A7—hypothyroidism	0.00103	0.0177	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—SLC5A7—hypothyroidism	0.00102	0.0177	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Liotrix—hypothyroidism	0.00102	0.00582	CcSEcCtD
Lisdexamfetamine—Asthenia—Liotrix—hypothyroidism	0.000991	0.00567	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Liotrix—hypothyroidism	0.000945	0.00541	CcSEcCtD
Lisdexamfetamine—Dizziness—Liotrix—hypothyroidism	0.000914	0.00523	CcSEcCtD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000898	0.0155	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Liotrix—hypothyroidism	0.000879	0.00503	CcSEcCtD
Lisdexamfetamine—Rash—Liotrix—hypothyroidism	0.000871	0.00498	CcSEcCtD
Lisdexamfetamine—Dermatitis—Liotrix—hypothyroidism	0.00087	0.00498	CcSEcCtD
Lisdexamfetamine—Headache—Liotrix—hypothyroidism	0.000866	0.00495	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000861	0.0149	CbGpPWpGaD
Lisdexamfetamine—Nausea—Liotrix—hypothyroidism	0.000821	0.0047	CcSEcCtD
Lisdexamfetamine—SLC18A2—adrenal gland—hypothyroidism	0.000813	0.0753	CbGeAlD
Lisdexamfetamine—SLC18A2—blood—hypothyroidism	0.000813	0.0752	CbGeAlD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000797	0.0138	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—thyroid gland—hypothyroidism	0.000785	0.0726	CbGeAlD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000729	0.0126	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—testis—hypothyroidism	0.000673	0.0622	CbGeAlD
Lisdexamfetamine—SLC18A2—Neuronal System—NEFL—hypothyroidism	0.00066	0.0114	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000646	0.0112	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—liver—hypothyroidism	0.000636	0.0588	CbGeAlD
Lisdexamfetamine—SLC18A2—cerebellum—hypothyroidism	0.000621	0.0575	CbGeAlD
Lisdexamfetamine—SLC6A3—Neuronal System—SLC5A7—hypothyroidism	0.000611	0.0106	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000604	0.0105	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—gonad—hypothyroidism	0.00057	0.0527	CbGeAlD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000551	0.00952	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000535	0.00926	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000514	0.00888	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—testis—hypothyroidism	0.000509	0.0471	CbGeAlD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—VAV3—hypothyroidism	0.000497	0.00859	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—adrenal gland—hypothyroidism	0.000496	0.0459	CbGeAlD
Lisdexamfetamine—SLC6A3—cerebellum—hypothyroidism	0.00047	0.0435	CbGeAlD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC5A5—hypothyroidism	0.000462	0.008	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000456	0.00789	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—TRH—hypothyroidism	0.000439	0.00759	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000433	0.00749	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—testis—hypothyroidism	0.000411	0.038	CbGeAlD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC5A5—hypothyroidism	0.00041	0.00709	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—NEFL—hypothyroidism	0.000393	0.0068	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000392	0.00679	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000371	0.00641	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000341	0.0059	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000328	0.00568	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000307	0.00531	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000291	0.00504	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000291	0.00503	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000272	0.0047	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000259	0.00448	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000259	0.00448	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000258	0.00447	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—AVP—hypothyroidism	0.00023	0.00399	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000229	0.00397	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—TRH—hypothyroidism	0.000221	0.00383	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.00022	0.00381	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000206	0.00357	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000203	0.00352	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—TSHB—hypothyroidism	0.000197	0.00341	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—TSHR—hypothyroidism	0.000197	0.00341	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000173	0.003	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000153	0.00264	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000148	0.00256	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000131	0.00227	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TRH—hypothyroidism	0.000125	0.00216	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000117	0.00202	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AVP—hypothyroidism	0.000116	0.00201	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TRH—hypothyroidism	0.000114	0.00196	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TSHR—hypothyroidism	0.000111	0.00193	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TSHB—hypothyroidism	0.000111	0.00193	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000103	0.00179	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000101	0.00175	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TSHR—hypothyroidism	0.000101	0.00175	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TSHB—hypothyroidism	0.000101	0.00175	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CLTC—hypothyroidism	7.76e-05	0.00134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—POMC—hypothyroidism	7.72e-05	0.00134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—VAV3—hypothyroidism	6.82e-05	0.00118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TRH—hypothyroidism	6.71e-05	0.00116	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AVP—hypothyroidism	6.57e-05	0.00114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—VAV3—hypothyroidism	6.19e-05	0.00107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TSHB—hypothyroidism	5.98e-05	0.00103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TSHR—hypothyroidism	5.98e-05	0.00103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AVP—hypothyroidism	5.97e-05	0.00103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SH2B3—hypothyroidism	5.33e-05	0.000922	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—POMC—hypothyroidism	4.37e-05	0.000755	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—POMC—hypothyroidism	3.96e-05	0.000686	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRL—hypothyroidism	3.95e-05	0.000684	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VAV3—hypothyroidism	3.66e-05	0.000633	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AVP—hypothyroidism	3.52e-05	0.000609	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—POMC—hypothyroidism	2.34e-05	0.000405	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1—hypothyroidism	2.25e-05	0.00039	CbGpPWpGaD
